<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158300</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000680634</org_study_id>
    <secondary_id>U01CA081457</secondary_id>
    <secondary_id>PBTC-031</secondary_id>
    <secondary_id>PTC299-ONC-010-PBT</secondary_id>
    <nct_id>NCT01158300</nct_id>
  </id_info>
  <brief_title>PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors</brief_title>
  <official_title>Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in&#xD;
      treating young patients with recurrent or refractory primary central nervous system tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To estimate the maximum-tolerated dose and the recommended phase II dose of VEGF&#xD;
           inhibitor PTC299 (PTC299) in pediatric patients with recurrent or progressive primary&#xD;
           central nervous system (CNS) tumors.&#xD;
&#xD;
        -  To evaluate and characterize the adverse events associated with this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  To evaluate and characterize the pharmacokinetics and pharmacodynamics of this regimen&#xD;
           in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To investigate the relationships between PTC299 plasma exposure and other outcomes&#xD;
           measures.&#xD;
&#xD;
        -  To evaluate the antitumor activity of this regimen in these patients.&#xD;
&#xD;
        -  To evaluate changes in angiogenic and inflammatory markers in the blood and the&#xD;
           relationship between these changes and other outcome measures.&#xD;
&#xD;
        -  To obtain preliminary evidence of biologic activity of PTC299 by using magnetic&#xD;
           resonance diffusion to assess tumor cellularity.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive oral VEGF inhibitor PTC299 twice or thrice daily. Treatment repeats every 28&#xD;
      days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected at baseline and periodically during study for pharmacokinetic and&#xD;
      pharmacodynamic studies by ELISA.&#xD;
&#xD;
      After completion of study therapy, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose</measure>
    <time_frame>First four weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the first day of treatment until 30 days after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of study participants with complete response or partial response to the study treatment</measure>
    <time_frame>Every 8 weeks</time_frame>
    <description>Brain images to assess partial or complete response are performed every 8 weeks after the first dose of the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day 1 and day 28 of course 1</time_frame>
    <description>Blood samples from study participants will be collected on day 1 and day 28 of course 1 for standard full pharmacokinetic studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood angiogenic markers and cytokines at discontinuation or completion of treatment</measure>
    <time_frame>Before the first dose of drug on day 1 of course 1 and at the discontinuation or completion of treatment</time_frame>
    <description>Blood samples will be collected and analyzed on Day 1 of pre-AM dosing at baseline and at the discontinuation or completion of treatment. Changes from baseline in blood angiogenic markers and cytokines (VEGF-A, VEGF-C, VEGF-D, PlGF, VEGFR-1, VEGFR-2, IL-6, and IL-8) will be assessed.</description>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEGF inhibitor PTC299</intervention_name>
    <description>This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of primary central nervous system (CNS) malignancy&#xD;
             at time of diagnosis or recurrence&#xD;
&#xD;
               -  Histology verification not required for intrinsic brain stem tumors and optic&#xD;
                  pathway gliomas&#xD;
&#xD;
                    -  Must have radiographic evidence of progression&#xD;
&#xD;
          -  Recurrent, progressive, or refractory disease to standard therapy and for which there&#xD;
             is no known curative therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 50-100% (patients &gt; 16 years of age) OR Lansky PS&#xD;
             50-100% (patients ≤ 16 years of age)&#xD;
&#xD;
          -  Body weight ≥ 15 kg and ≤ 100 kg&#xD;
&#xD;
          -  Patients with neurological deficits allowed provided they are stable for ≥ 1 week&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
          -  ANC ≥ 1,000/μL (unsupported)&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL (unsupported)&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (may be supported)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 mL/min/1.73&#xD;
             m^2 OR serum creatinine normal based on age as follows:&#xD;
&#xD;
               -  0.8 mg/dL (≤ 5 years of age)&#xD;
&#xD;
               -  1.0 mg/dL (&gt; 5 to ≤ 10 years of age)&#xD;
&#xD;
               -  1.2 mg/dL (&gt; 10 to ≤ 15 years of age)&#xD;
&#xD;
               -  1.5 mg/dL (&gt; 15 years of age)&#xD;
&#xD;
          -  Urine protein/creatinine ratio &lt; 1.0&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 2.5 g/dL&#xD;
&#xD;
          -  PT and activated PTT ≤ 1.2 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No clinically significant unrelated systemic illness that would compromise the&#xD;
             patient's ability to tolerate protocol therapy, or would likely interfere with the&#xD;
             study procedures or results, including any of the following:&#xD;
&#xD;
               -  Serious infections including ongoing systemic bacterial, fungal, or viral&#xD;
                  infection&#xD;
&#xD;
               -  Significant cardiac, pulmonary, hepatic, or other organ dysfunction&#xD;
&#xD;
          -  Willing and able to comply with schedule visits, drug administration plan, laboratory&#xD;
             tests, including pharmacokinetic and pharmacodynamic assessments, or other study&#xD;
             procedures&#xD;
&#xD;
          -  No known coagulopathy or bleeding diathesis&#xD;
&#xD;
          -  No known history of drug-induced liver injury&#xD;
&#xD;
          -  No CNS, pulmonary, gastrointestinal, or urinary bleeding within the past month&#xD;
&#xD;
          -  No uncontrolled systemic hypertension (systolic BP or diastolic BP &gt; 95% percentile&#xD;
             for age)&#xD;
&#xD;
          -  No alcohol or drug addiction&#xD;
&#xD;
          -  Able to tolerate periodic MRI scans and gadolinium contrast&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from the acute toxic of all prior therapy (excluding alopecia and&#xD;
             neurotoxicity)&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for&#xD;
             nitrosourea)&#xD;
&#xD;
          -  At least 14 days since prior investigational or biological agent&#xD;
&#xD;
               -  At least 3 half-lives since prior biological agents that have a prolonged&#xD;
                  half-life&#xD;
&#xD;
          -  At least 3 half-lives since prior monoclonal antibody&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior total-body irradiation, craniospinal radiotherapy, or&#xD;
             radiotherapy to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 90 days since prior allogeneic bone marrow transplantation&#xD;
&#xD;
               -  No active graft-versus-host disease&#xD;
&#xD;
          -  Concurrent dexamethasone or other corticosteroids allowed provided dose is stable for&#xD;
             ≥ 7 days&#xD;
&#xD;
          -  At least 1 week since prior colony-forming growth factors (e.g., filgrastim,&#xD;
             sargramostim, erythropoietin)&#xD;
&#xD;
               -  At least 14 days since long-acting colony-forming growth factor formulations&#xD;
                  (e.g., pegfilgrastim)&#xD;
&#xD;
          -  More than 4 weeks since prior major surgical procedures&#xD;
&#xD;
               -  More than 2 weeks since prior intermediate surgical procedures&#xD;
&#xD;
               -  More than 7 days since minor surgical procedures&#xD;
&#xD;
          -  No other concurrent anticancer or investigational drug therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger J. Packer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>May 1, 2015</last_update_submitted>
  <last_update_submitted_qc>May 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood malignant germ cell tumor</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent childhood central nervous system embryonal tumor</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood spinal cord neoplasm</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>childhood central nervous system choriocarcinoma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood central nervous system germinoma</keyword>
  <keyword>childhood central nervous system mixed germ cell tumor</keyword>
  <keyword>childhood central nervous system teratoma</keyword>
  <keyword>childhood central nervous system yolk sac tumor</keyword>
  <keyword>childhood astrocytoma</keyword>
  <keyword>childhood medulloepithelioma</keyword>
  <keyword>childhood meningioma</keyword>
  <keyword>childhood mixed glioma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood pineal parenchymal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

